FPH’s Donal O’Dwyer to retire, Graham McLean appointed

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Fisher & Paykel Healthcare Director Donal O’Dwyer to retire, Graham McLean to join the
Board as non-executive director

Auckland, New Zealand, 24 July 2023 - Fisher & Paykel Healthcare Director Donal O’Dwyer has
announced his intention to retire as a director of the company with effect from 31 December 2023.

The company also announced it has appointed Graham McLean to the Board as a non-executive
director with effect from 1 October 2023.

“Donal has provided a wealth of knowledge and experience to the Board during his 11-year
tenure,” said Board Chair Scott St John. “His global leadership credentials in medical technologies
have enabled him to make a significant contribution and we thank him for this.

“With Donal preparing to step away, we are very pleased to have secured Graham as a director,”
said Mr St John. “Similar to Donal, Graham has carved out a successful global career in the
medical device field and we are confident he will be an impactful addition to the Board.”

An Australian resident, Mr McLean is currently a director and CEO of CleanSpaceHoldings and
chair of Universal Biosensors, two ASX-listed healthcare companies. Graham previously spent 16
years as an executive at leading medical device manufacturer Stryker Corporation, most recently
as President of the Asia Pacific region situated in Hong Kong and Singapore.

His tenure with Stryker also included stints as President of Japan and President of the South
Pacific region, while his earlier career featured finance, audit and commercial positions at Lion
Nathan, McVitie’s Ltd and Unilever.

The Fisher & Paykel Healthcare Board has determined that Mr McLean will be an independent
director of the Board. He will also serve as a member of the Audit and Risk Committee, effective 1
October 2023.

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and
systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive
sleep apnea. The company’s products are sold in over 120 countries worldwide. For more
information about the company, visit our website www.fphcare.com.

Media & Investor Contacts:

Hayden Brown
Head of Capital Markets & Investor
Relations
hayden.brown@fphcare.co.nz
+64 (0) 27 807 8073
Dan Adolph
Senior Communications & Investor Relations
Manager
daniel.adolph@fphcare.co.nz
+64 (0) 22 511 4050


Authorised by Raelene Leonard, General Counsel and Company Secretary.